Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see the safety and efficient of neoantigen reactive T cells
(NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of
Chinese patients with advanced refractory solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School